A team of researchers has found out that a previously known anti-viral drug can speed up recovery of Covid-19 patients. An international team of researchers has claimed that interferon(IFN)-a2b – an antiviral drug- will help is treating the Covid-19 patients. The study is published in the journal Frontiers in Immunology.
“Rather than developing a virus-specific antiviral for each new virus outbreak, we should consider interferons as the ‘first responders’ in terms of treatment,” said study lead researcher Dr Eleanor Fish professor in the University of Toronto, Canada.
The research team considered IFN-a therapy for Covid-19 after they demonstrated interferon provided therapeutic benefit during the SARS outbreak of 2002 and 2003. They found that treatment with this drug, which has been used clinically for many years, significantly reduced the duration of detectable virus in the upper respiratory tract, on average by about seven days.
It also reduced blood levels of interleukin(IL)-6 and C-reactive protein (CRP), two inflammatory proteins found in Covid-19 patients. For the findings, the researchers conducted this exploratory study on a group of 77 patients with Covid-19 in Wuhan, China.
Another study, published in the journal The Lancet, stated that the two-week course of antiviral therapy that combines the power of three antiviral drugs has shown promise in treating hospitalised patients with mild to moderate Covid-19 virus. The drug combination tested in the trial included — interferon beta-1b which was developed to treat multiple sclerosis (MS), lopinavir-ritonavir which is normally used to treat HIV and ribavirin, an oral hepatitis C virus drug.
Post Your Comments